Astrana Health (ASTH) director receives 4,525 restricted stock award

Rhea-AI Filing Summary

Schmidt David reported acquisition or exercise transactions in this Form 4 filing.

Astrana Health, Inc. director David Schmidt received a grant of 4,525 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost to him under the company’s 2024 Equity Incentive Plan and will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. After this award, he holds a total of 36,019 common shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Schmidt David

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,525	$0.00	--

Holdings After Transaction: Common Stock — 36,019 shares (Direct, null)

Footnotes (1)

1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Restricted stock grant: 4,525 shares Post-grant holdings: 36,019 shares Vesting date: Earlier of June 10, 2027 or 2027 meeting +1 more

4 metrics

Restricted stock grant 4,525 shares Common stock award to director on June 10, 2026

Post-grant holdings 36,019 shares Director’s total direct common stock after award

Vesting date Earlier of June 10, 2027 or 2027 meeting Restricted shares vesting condition

Grant price $0.0000 per share Equity compensation; no cash paid by director

Key Terms

Restricted shares, 2024 Equity Incentive Plan, annual meeting of stockholders

3 terms

Restricted shares financial

"Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan"

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

2024 Equity Incentive Plan financial

"granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027"

annual meeting of stockholders financial

"will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 04:21 PM Accepted by SEC EDGAR 06/12/2026 - 04:21 PM Learn about SEC filing dates

FAQ

What insider transaction did Astrana Health (ASTH) report for David Schmidt?

Astrana Health reported that director David Schmidt received 4,525 shares of restricted common stock as an equity grant. The award was made at no cash cost to him under the 2024 Equity Incentive Plan and vests by 2027.

Is the ASTH Form 4 for David Schmidt a stock purchase or a grant?

The ASTH Form 4 shows a stock grant, not an open-market purchase. Schmidt acquired 4,525 restricted shares as a compensation award under Astrana Health’s 2024 Equity Incentive Plan, with future vesting conditions attached to the shares.

When do David Schmidt’s 4,525 restricted ASTH shares vest?

The 4,525 restricted Astrana Health shares vest on the earlier of June 10, 2027 or the date of the company’s 2027 annual meeting of stockholders. Vesting must occur before Schmidt fully owns the granted shares without restrictions.

How many Astrana Health (ASTH) shares does David Schmidt own after this grant?

After this grant, David Schmidt beneficially owns 36,019 shares of Astrana Health common stock directly. This total includes the 4,525 restricted shares that are scheduled to vest no later than the company’s 2027 annual meeting of stockholders.

What plan governs the restricted stock granted to David Schmidt at Astrana Health?

The restricted stock granted to David Schmidt was issued under Astrana Health’s 2024 Equity Incentive Plan. This plan authorizes equity-based compensation awards, including restricted shares that typically vest over time or upon specified corporate events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schmidt David

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVE, 2ND FLOOR

(Street)

ALHAMBRA CALIFORNIA 91801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		4,525(1)	A	$0	36,019(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

2. Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ Kathy Diep, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)